2. Search Result
Search Result
Results for "

TYK2+inhibitor

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

12

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-150096
    Zasocitinib
    1 Publications Verification

    NDI-034858; TAK-279

    		 JAK Inflammation/Immunology
    Zasocitinib (NDI-034858) is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM .
    Zasocitinib
  • HY-112708
    Brepocitinib
    3 Publications Verification

    PF-06700841

    		 JAK Inflammation/Immunology
    Brepocitinib (PF-06700841) is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively .
    Brepocitinib
  • HY-15999
    Cerdulatinib
    Maximum Cited Publications
    8 Publications Verification

    PRT062070; PRT2070

    		 JAK Syk Cancer
    Cerdulatinib (PRT062070) is a selective Tyk2 inhibitor with an IC50 of 0.5 nM. Cerdulatinib (PRT062070) also is a dual JAK and SYK inhibitor with IC50s of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively.
    Cerdulatinib
  • HY-131968
    BMS-986202
    1 Publications Verification

    		 JAK Cytochrome P450 Inflammation/Immunology
    BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC50 value of 0.19 nM and a Ki of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC50 value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .
    BMS-986202
  • HY-160144S
    Lomedeucitinib

    BMS-986322

    		 Isotope-Labeled Compounds JAK Inflammation/Immunology
    Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor [2] .
    Lomedeucitinib
  • HY-16640
    TCJL37

    		JAK Inflammation/Immunology
    TCJL37 is a potent, selective, and orally bioavailable TYK2 inhibitor with a Ki of 1.6 nM. TCJL37 can be used for the research of inflammatory bowel diseases (IBD) .
    TCJL37
  • HY-120469
    2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide

    		JAK Inflammation/Immunology
    GDC-046 is a potent, selective, and orally bioavailable TYK2 inhibitor with Kis of 4.8, 0.7, 0.7, and 0.4 nM for TYK2, JAK1, JAK2, and JAK3, respectively .
    2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
  • HY-112708A
    Brepocitinib P-Tosylate
    3 Publications Verification

    PF-06700841 P-Tosylate

    		 JAK Inflammation/Immunology
    Brepocitinib (PF-06700841) P-Tosylate is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. Brepocitinib P-Tosylate also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively .
    Brepocitinib P-Tosylate
  • HY-153701S
    Envudeucitinibum

    Envudeucitinib; ESK-001

    		 JAK Interleukin Related IFNAR Isotope-Labeled Compounds Inflammation/Immunology
    Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases [2].
    Envudeucitinibum
  • HY-161683
    Tyk2-IN-19

    		JAK Neurological Disease
    Tyk2-IN-19 (Compound 1) is an orally active and blood-brain barrier (BBB) permeable Tyk2 inhibitor. Tyk2-IN-19 can be used for study of neurodegenerative diseases .
    Tyk2-IN-19
  • HY-156961
    Cadefrecitinib

    GLPG3667

    		 JAK Inflammation/Immunology
    Cadefrecitinib (GLPG3667) is a reversible, ATP-competitive and orally active TYK2 inhibitor with an IC50 of 2.3 nM. Cadefrecitinib inhibits IFNα/pSTAT1, and the IC50 values ​​in human peripheral blood mononuclear cell (PBMC) and whole blood assays are 70 nM and 623 nM, respectively. Cadefrecitinib has the potential for the study of inflammatory and autoimmune diseases .
    Cadefrecitinib
  • HY-101762
    TyK2-IN-2

    		JAK Phosphodiesterase (PDE) Inflammation/Immunology
    TyK2-IN-2 (Compoud 18) is a potent and selective TYK2 inhibitor with IC50s of 7 nM, 0.1 μM and 0.05 μM for TYK2 JH2, IL-23 and IFNα, respectively. TyK2-IN-2 also inhibits phosphodiesterase 4 (PDE4) with an IC50 of 62 nM. TyK2-IN-2 can be used for the research of inflammatory and autoimmune diseases .
    TyK2-IN-2
  • HY-111745
    Tyk2-IN-5

    		JAK Inflammation/Immunology
    Tyk2-IN-5 (compound 6) is a potent, selective and orally active tyrosine kinase 2 (Tyk2) inhibitor that acts on the JH2 structural domain. Tyk2-IN-5 shows a Ki value of 0.086 nM for Tyk2 JH2 and an IC50 value of 25 nM for IFNα. Tyk2-IN-5 efficiently inhibits the production of IFNγ in a pharmacodynamic rat model and is fully efficacious in a rat model of arthritis .
    Tyk2-IN-5
  • HY-175310S
    Voderdeucitinib

    		JAK Inflammation/Immunology
    Voderdeucitinib (Compoudn I) is a TYK2 inhibitor with an anti-inflammatory activity. Voderdeucitinib can be used for inflammatory and autoimmune disease research, such as rheumatoid arthritis (RA), multiple sclerosis and intestinal bowel disease (IBD) .
    Voderdeucitinib
  • HY-177130S
    Socrodeucitinib

    		JAK Inflammation/Immunology
    Socrodeucitinib (Compound Example 58) is an orally active and selective tyrosine kinase 2 (TYK2) inhibitor with an IC50 value of 1.41 nM. Socrodeucitinib exerts anti-inflammatory activity by inhibiting TYK2-mediated cytokine signaling pathways and reducing the secretion of inflammatory factors. Socrodeucitinib is promising for research of autoimmune diseases such as psoriasis and inflammatory diseases .
    Socrodeucitinib
  • HY-144031S
    Tyk2-IN-8

    		Isotope-Labeled Compounds JAK Inflammation/Immunology
    Tyk2-IN-8 (compound 3) is a selective Tyk-2 inhibitor with an IC50 of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC50 of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease .
    Tyk2-IN-8
  • HY-175983
    JAK1/TYK2-IN-5

    		JAK Cancer
    JAK1/TYK2-IN-5 (compound A1) is a JAK1/TYK2 inhibitor with Ki values of 0.0044 nM, 0.02 nM, 6.9 μM, 0.79 μM, 0.21 μM and 0.55 μM for TYK2 JH2, JAK1 JH2, JAK1 JH1, JAK2 JH1, JAK3 JH1 and TYK2 JH1, respectiverly. JAK1/TYK2-IN-5 inhibts IFNα induced TYK2/JAK1-mediated STAT activation .
    JAK1/TYK2-IN-5
  • HY-143884
    JAK2/TYK2-IN-1
    1 Publications Verification

    		 JAK Inflammation/Immunology
    JAK2/TYK2-IN-2 is a potent and selective TYK2 inhibitor with IC50 values of 9 and 157 nM for TYK2 and JAK2, respectively. JAK2/TYK2-IN-2 has anti-inflammatory activity .
    JAK2/TYK2-IN-1
  • HY-163304
    Tyk2-IN-16

    		JAK Cancer
    Tyk2-IN-16 is a selective and potent TYK2 inhibitor with an IC50 of <10 nM for TYK2-JH2. Tyk2-IN-16 inhibits pSTAT4 with an IC50 of <10 nM in NK92 cells (WO2023220046A1; compound 184) .
    Tyk2-IN-16
  • HY-160144S2
    (rac)-Lomedeucitinib

    (rac)-BMS-986322

    		 Drug Isomer Others
    (rac)-Lomedeucitinib ((rac)-BMS-986322) is the racemate of Lomedeucitinib. Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor. Lomedeucitinib has anti-inflammatory activity and significant inhibitory effect on IFNα (IC50=0.047 μM) production downstream of IL-12/TYK2. Lomedeucitinib is indicated for the study of plaque psoriasis and pruritus [2] .
    (rac)-Lomedeucitinib
  • HY-163305
    Tyk2-IN-17

    		JAK Inflammation/Immunology
    Tyk2-IN-17 (compound 185) is a potent TYK2 inhibitor .
    Tyk2-IN-17
  • HY-160144S1
    (S)-Lomedeucitinib

    (S)-BMS-986322

    		 JAK Inflammation/Immunology
    (S)-Lomedeucitinib ((S)-BMS-986322) is a S-enantiomer of Lomedeucitinib (HY-160144S). Lomedeucitinib is a tyrosine protein kinase (TYK2) inhibitor .
    (S)-Lomedeucitinib
  • HY-158692
    Tyk2-IN-18

    		JAK Cancer
    Tyk2-IN-18 (compound 86) is a potent tyrosine kinase 2 (Tyk2) inhibitor. Tyk2-IN-18 inhibits JAK2-JH2, with an IC50 of ＜10 nM [2].
    Tyk2-IN-18
  • HY-149892S
    TYK2 JH2-IN-1-d3

    		JAK Cancer
    TYK2?JH2-IN-1-d3 is the a deuterated, orally active and selective TYK2 inhibitor (compound 4h), targeting to JH2 domain (IC50=0.1 nM) .
    TYK2 JH2-IN-1-d3
  • HY-163312S
    Tyk2-IN-18-d5

    		JAK Inflammation/Immunology
    Tyk2-IN-18-d5 (Compound 13) is the deuterated TYK2 inhibitor, targeting to JH2 domain. Tyk2-IN-18-d5 can be used for the research of inflammatory and autoimmune diseases .
    Tyk2-IN-18-d5
  • HY-163303
    Tyk2-IN-15

    		JAK Inflammation/Immunology
    Tyk2-in-15 (Compound 97) is a selective tyrosine kinase 2 (Tyk2) inhibitor with IC50 value ≤ 10 nM for Tyk2-JH2. Tyk2-IN-15 can be used in the study of inflammatory or autoimmune diseases .
    Tyk2-IN-15
  • HY-163314S
    Tyk2-IN-18-d3

    		JAK Interleukin Related IFNAR Inflammation/Immunology
    Tyk2-IN-18-d3 (Compound 18) is a Tyk2 inhibitor with an IC50 value of < 30 nM for both IL-23 and IFNα. Tyk2-IN-18-d3 can be used for research on autoimmune diseases .
    Tyk2-IN-18-d3
  • HY-168269
    Tyk2-IN-20

    		JAK Cancer
    Tyk2-IN-20 (Example 289) is a potent Tyk2 inhibitor with an IC50 of <5 nM. Tyk2-IN-20 als inhibits JAK1, JAK2, and JAK3 with IIC50 values of <100 nM. Tyk2-IN-20 can be used for the study of inflammatory diseases .
    Tyk2-IN-20
  • HY-144032
    Tyk2-IN-9

    		JAK Inflammation/Immunology
    Tyk2-IN-9 (Compound 26) is a selective Tyk-2 inhibitor with IC50s of 0.076 and 1.8 nM for TYK2-JH2 and JAK1-JH2, respectively. Tyk2-IN-9 can be used for the research of inflammatory or autoimmune disease .
    Tyk2-IN-9
  • HY-144087
    TYK2-IN-11

    		JAK Inflammation/Immunology
    TYK2-IN-11 (Compound 5B) is a selective Tyk-2 inhibitor with IC50s of 0.016 and 0.31 nM for TYK2-JH2 and JAK1-JH2, respectively. TYK2-IN-11 can be used for the research of inflammatory or autoimmune disease .
    TYK2-IN-11
  • HY-101762R
    TyK2-IN-2 (Standard)

    		Reference Standards JAK Phosphodiesterase (PDE) Inflammation/Immunology
    TyK2-IN-2 (Standard) is the analytical standard of TyK2-IN-2 (HY-101762). This product is intended for research and analytical applications. TyK2-IN-2 (Compoud 18) is a potent and selective TYK2 inhibitor with IC50s of 7 nM, 0.1 μM and 0.05 μM for TYK2 JH2, IL-23 and IFNα, respectively. TyK2-IN-2 also inhibits phosphodiesterase 4 (PDE4) with an IC50 of 62 nM. TyK2-IN-2 can be used for the research of inflammatory and autoimmune diseases .
    TyK2-IN-2 (Standard)
  • HY-166594S
    Deucravacitinib-13C,d3

    		Isotope-Labeled Compounds IFNAR Interleukin Related JAK Inflammation/Immunology
    Deucravacitinib- 13C,d3 is the 13C- and deuterium labeled Deucravacitinib. Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis [2].
    Deucravacitinib-13C,d3
  • HY-178913
    Tyk2-IN-23

    		JAK STAT Inflammation/Immunology
    Tyk2-IN-23 is a potent, orally active, selective TYK2 inhibitor (IC50 = 18 nM), exhibiting more than > 70-fold selectivity over JAK1/2/3 isoforms. Tyk2-IN-23 potently inhibits p-STAT3 in TYK2-dependent signaling activated by IFN-α and IL-10. Tyk2-IN-23 potently inhibits IFN-α-induced STAT1 phosphorylation in H9 cells. Tyk2-IN-23 can be used for the study of alopecia areata and allergic Rhinitis .
    Tyk2-IN-23

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: